Shee K, Jiang A, Varn FS, et al. Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER breast cancer. FASEB J. 2019;33(2):1644-1657. doi:10.1096/fj.201801241R.
Sadler JBA, Wenzel DM, Strohacker LK, et al. A cancer-associated polymorphism in ESCRT-III disrupts the abscission checkpoint and promotes genome instability. Proc Natl Acad Sci U S A. 2018;115(38):E8900-E8908. doi:10.1073/pnas.1805504115.
Andrews LB, Nielsen AAK, Voigt CA. Cellular checkpoint control using programmable sequential logic. Science. 2018;361(6408). doi:10.1126/science.aap8987.
Goel S, DeCristo MJ, McAllister SS, Zhao JJ. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. Trends Cell Biol. 2018;28(11):911-925. doi:10.1016/j.tcb.2018.07.002.
Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471-475. doi:10.1038/nature23465.
Chan EM, Shibue T, McFarland JM, et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature. 2019;568(7753):551-556. doi:10.1038/s41586-019-1102-x.
Hayes TK, Luo F, Cohen O, et al. A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma. Cancer Res. 2019;79(9):2352-2366. doi:10.1158/0008-5472.CAN-18-2711.
Shee K, Yang W, Hinds JW, et al. Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. J Exp Med. 2018;215(3):895-910. doi:10.1084/jem.20171818.
Puissant A, Frumm SM, Alexe G, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013;3(3):308-23. doi:10.1158/2159-8290.CD-12-0418.
Bar-Nur O, Brumbaugh J, Verheul C, et al. Small molecules facilitate rapid and synchronous iPSC generation. Nat Methods. 2014;11(11):1170-6. doi:10.1038/nmeth.3142.